These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
425 related articles for article (PubMed ID: 8106148)
1. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148 [TBL] [Abstract][Full Text] [Related]
2. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227 [TBL] [Abstract][Full Text] [Related]
3. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247 [TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144 [TBL] [Abstract][Full Text] [Related]
6. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973 [TBL] [Abstract][Full Text] [Related]
7. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932 [TBL] [Abstract][Full Text] [Related]
8. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Jain N; Lam YM; Pym J; Campling BG Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677 [TBL] [Abstract][Full Text] [Related]
10. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746 [TBL] [Abstract][Full Text] [Related]
11. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. Wolverton JS; Danks MK; Schmidt CA; Beck WT Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902 [TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551 [TBL] [Abstract][Full Text] [Related]
13. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance. Politi PM; Sinha BK Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628 [TBL] [Abstract][Full Text] [Related]
14. Combined modalities of resistance in etoposide-resistant human KB cell lines. Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393 [TBL] [Abstract][Full Text] [Related]
15. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057 [TBL] [Abstract][Full Text] [Related]
16. Novobiocin-induced accumulation of etoposide (VP-16) in WEHI-3B D+ leukemia cells. Lorico A; Rappa G; Sartorelli AC Int J Cancer; 1992 Dec; 52(6):903-9. PubMed ID: 1334054 [TBL] [Abstract][Full Text] [Related]
17. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
18. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). Rappa G; Lorico A; Sartorelli AC Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186 [TBL] [Abstract][Full Text] [Related]
19. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Friche E; Danks MK; Schmidt CA; Beck WT Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312 [TBL] [Abstract][Full Text] [Related]
20. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells. Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]